AMA Arch Intern Med. 1955;96(2):277-280. doi:10.1001/archinte.1955.00250130151014.
Text Size: A A A
Published online

URETHAN since 1946 has been used extensively in the treatment of multiple myeloma with a good palliative response in somewhat more than 50% of the cases. The margin of safety in the use of this chemotherapeutic agent has appeared to be fairly broad. Moderate leucopenia and gastrointestinal symptoms are the most frequent complications. Rare reports have appeared of agranulocytosis and aplastic anemia in patients on urethan, and reversible central nervous system symptoms have been described, with improvement following cessation of therapy.6 In the past few years convincing evidence has accumulated from both experimental and clinical data indicating that in the dosage range required for effective therapy urethan may occasionally produce massive hepatic necrosis.* Five cases of acute massive centrilobular liver necrosis in patients with multiple myeloma on this treatment have been reported in the last five years.† Findings suggestive of renal damage produced by urethan have been reported in


Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
First page PDF preview





Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment


Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 13

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.